Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mineralys Therapeutics, Inc. (Nasdaq: MLYS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor, through clinical development. As a clinical-stage biopharmaceutical company focused on hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other aldosterone-driven diseases, Mineralys uses SEC filings to report financial results, capital-raising activities and other material events.
Current and prospective investors can review Form 8-K filings where Mineralys reports quarterly financial results and corporate updates, as well as transactions such as underwritten public offerings of common stock and changes to at-the-market equity programs. These documents often reference the company’s clinical progress with lorundrostat, including pivotal trials like Launch-HTN and Advance-HTN, Phase 2 programs such as Explore-CKD and Explore-OSA, and steps toward a potential New Drug Application (NDA) with the U.S. Food and Drug Administration.
Over time, the filings set is expected to include annual reports on Form 10-K, quarterly reports on Form 10-Q, and additional 8-Ks that elaborate on risk factors, liquidity, research and development spending, and the company’s dependence on the success of lorundrostat and key licensing arrangements. Investors may also monitor registration statements and prospectus supplements related to equity offerings, as reflected in referenced Form S-3 filings.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points, such as trial-related disclosures, financing terms and forward-looking statements. Real-time updates from EDGAR, combined with tools to track items like material events and offering details, help users quickly understand how Mineralys Therapeutics’ regulatory and financial reporting aligns with its clinical and regulatory strategy for lorundrostat.
Mineralys Therapeutics, Inc. Chief Medical Officer Rodman David Malcom reported option and stock transactions in company shares. On February 17, 2026, he exercised a stock option for 417 shares of common stock at $15.44 per share and then sold 417 shares at $27.59 per share.
After these transactions, he directly owned 44,089 shares of common stock and 5,417 stock options. The filing states the trades were carried out under a Rule 10b5-1 trading plan adopted on October 6, 2025, indicating they were pre-arranged rather than discretionary trades.
Mineralys Therapeutics insider David Rodman has filed a Form 144 notice to sell common stock. The filing covers 417 shares of Mineralys Therapeutics, Inc. common stock to be sold through Merrill Lynch on or about February 17, 2026 on the NASDAQ market, with an aggregate market value of $11,505.03.
The 417 shares were acquired the same day through the exercise of employee stock options via a broker-assisted cashless exercise. The notice also lists prior sales of Mineralys common stock by David Rodman over the past three months, including 192,715 shares sold on January 5, 2026 for gross proceeds of $6,749,100.06 and 70,037 shares sold on January 2, 2026 for $2,511,919.03.
Mineralys Therapeutics (MLYS) Chief Medical Officer Rodman David Malcom reported option exercises and share sales in mid-February 2026. On February 12 and 13, 2026, he exercised stock options for 6,349, 3,541 and 4,166 common shares at exercise prices of $1.08, $10.20 and $14.25 per share.
He then sold portions of the resulting common stock in open‑market transactions at weighted‑average prices of $28.9353, $29.6387, $27.33 and $27.5835, all under a Rule 10b5‑1 trading plan adopted on October 6, 2025. After these transactions, he directly owned 44,089 shares of common stock, along with multiple remaining stock option positions.
Mineralys Therapeutics, Inc. received an amended Schedule 13G showing that investment entities affiliated with Catalys Pacific and individual reporting person Brian Taylor Slingsby collectively report beneficial ownership of 8,002,738 shares of common stock, or 10.1% of the class as of December 31, 2025.
The filing states that 7,903,838 shares are held of record by Catalys Pacific Fund, LP, with an additional 98,900 shares underlying stock options exercisable within 60 days of December 31, 2025. All reporting persons report shared voting and dispositive power over these 8,002,738 shares, and no sole voting or dispositive power.
Mineralys Therapeutics insider David Rodman has filed a Form 144 notice to sell common stock. The filing covers 14,055 shares of Mineralys Therapeutics common stock to be sold through Merrill Lynch on the NASDAQ around 02/13/2026, with an aggregate market value of 385,732.29 and 79,139,956 shares outstanding.
The shares to be sold were acquired by exercising employee stock options, including 7,707 shares on 02/13/2026 through a broker-assisted cashless exercise and 6,348 shares on 02/12/2025 for cash. Over the past three months, Rodman has reported several sales of Mineralys common stock, including 192,715 shares on 01/05/2026 for gross proceeds of 6,749,100.06 and additional smaller transactions in January and February 2026.
Mineralys Therapeutics, Inc. insider trading plan disclosure: A person named David Rodman has filed a notice of intent to sell 6,349 shares of Mineralys Therapeutics common stock on NASDAQ through Merrill Lynch, with an aggregate market value of
The 6,349 shares were acquired on
Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reported option exercises and share sales. On February 9, 2026, he exercised stock options covering 2,171 shares of common stock at $16 per share and received the underlying common shares.
On the same date, he sold 2,171 shares of Mineralys Therapeutics common stock in an open-market transaction at an average price of $30.21 per share, leaving him with 50,437 common shares held directly and 26,047 stock options outstanding. The filing states these trades were made under a Rule 10b5-1 trading plan adopted on October 6, 2025.
Mineralys Therapeutics insider plans new stock sale
A holder of Mineralys Therapeutics common stock, identified in the filing as David Rodman, has filed a notice to sell 2,171 shares of common stock through Merrill Lynch on or about February 9, 2026 on the NASDAQ. The aggregate market value of this planned sale is listed as
The shares to be sold were acquired the same day via an exercise of employee stock options in a broker-assisted cashless transaction with Mineralys Therapeutics, Inc. Over the prior three months, the same seller completed multiple common stock sales, including 192,715 shares for gross proceeds of
FMR LLC and Abigail P. Johnson have disclosed a significant ownership position in Mineralys Therapeutics Inc. common stock. They report beneficial ownership of 5,017,509 shares, representing 6.3% of the company’s outstanding common stock as of the event date.
FMR LLC has sole voting power over 5,013,931 shares and sole dispositive power over 5,017,509 shares. Abigail P. Johnson holds sole dispositive power over the same 5,017,509 shares but no voting power. The filing states the shares were acquired in the ordinary course of business and not with the purpose of influencing control of Mineralys.
Mineralys Therapeutics Inc. reported that BlackRock, Inc. has become a 5.2% beneficial owner of its common stock. As of 12/31/2025, BlackRock reports beneficial ownership of 4,113,657 shares of Mineralys common stock, with sole voting power over 4,041,593 shares and sole dispositive power over 4,113,657 shares, and no shared voting or dispositive power.
BlackRock states the securities are held by certain of its business units in the ordinary course of business and not with the purpose or effect of changing or influencing control of Mineralys. Various underlying clients have rights to dividends or sale proceeds, but no single client has more than five percent of the total outstanding common shares.